Displaying 301 - 312 of 452
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Displaying 301 - 312 of 452